Starting in 2021, Medicare patients could have access to a new permanent home infusion benefit. The Center for Medicare &amp; Medicaid Services (CMS) proposed the benefit in July as part of <a href="https://homehealthcarenews.com/2019/07/cms-proposes-elimination-of-raps-250-million-medicare-payment-increase/">its proposed home health payment rule</a>, with the goal being to move more care into the home.While some view the proposed benefit as a win and an opportunity creator for home health care companies, others argue the benefit is &ldquo;deeply flawed&rdquo; and doesn&rsquo;t go far enough.Home infusion is the at-home delivery of a drug directly into a patient&rsquo;s vein through a needle or catheter. Currently, Medicare only offers home infusion benefits to certain patients.<figure><a href="https://servedbyadbutler.com/redirect.spark?MID=166549&plid=1007911&setID=335899&channelID=0&CID=279667&banID=519756400&PID=0&textadID=0&tc=1&mt=1567980739572479&sw=1024&sh=768&spr=1&hc=afbad17cca1767e6e930052500f787dc75006573&location="><img alt="" src="https://media-aws02.inloop.com/ins1/19a/9d94892fff82412dbfdeb2d4095b6e2a-contentimage?size=large" class=" aggr-main-image" /></a></figure>While Congress passed the 21st Century Cures Act in 2016 to offer a home infusion benefit, the start of those benefits was delayed until 2021. On top of that, reimbursement changes in recent years have made it difficult for patients already receiving Medicare-covered home infusions to afford the services.However, the aim of this proposed benefit, which would take effect in 2021, is to change that, giving the patients the choice to receive care in their homes.&ldquo;We are proud to announce the new permanent home infusion therapy benefit that will give patients the freedom to safely access critical treatments, such as chemotherapy, at home instead of traveling to the hospital or doctor&rsquo;s office, improving their quality of life,&rdquo; CMS Administrator Seema Verma said in a press release following the proposed rule&rsquo;s release.In addition to chemotherapy, other examples of home infusion include immune deficiency and anti-infective treatment. All three would be Medicare-reimbursable if the home infusion benefit takes effect.&ldquo;This is fantastic,&rdquo; Laizer Kornwasser, President and COO of CareCentrix, told Home Health Care News. &ldquo;We believe that patients want to be treated in the home when they&rsquo;re able to. This allows for patients to be treated in the home. It&rsquo;s a win-win for patients, and it provides tremendous opportunity for [home health] providers.&rdquo;Hartford, Connecticut-based CareCentrix is a post-acute and home health care solutions company that works with a network of providers to help ensure patients get the right services at the right time, in the right location. The company also takes on readmissions risk for post-acute care providers a full 90-days post-discharge, Kornwasser said.Overall, he says CareCentrix&rsquo;s home health clients are excited about the prospect of delivering home infusion using the proposed benefit in the years to come.&ldquo;From what I&rsquo;ve heard, people are embracing the fact that this will open up more volume coming to the home, and it will create opportunity,&rdquo; Kornwasser said.While many logistics surrounding how the proposed benefit will work remain unclear, CMS has proposed breaking home infusion medications down into three payment categories, in addition to paying higher reimbursements for initial home infusion visits, while slightly decreasing reimbursements to follow.On top of creating opportunities for home health providers, the benefit could also mean a huge cost savings for Medicare. The Congressional Budget Office previously estimated that a home infusion benefit could reduce Medicare spending by $372 million through 2026.&ldquo;As you move care into the home, costs go down,&rdquo; Kornwasser said. &ldquo;You&rsquo;re not paying all the fees that are associated with hospital settings. You&rsquo;re not paying for transportation. [And] you&rsquo;re also increasing compliance with therapy treatment by making it more convenient for the patient.&rdquo;<h3>&lsquo;Deep Flaws&rsquo; </h3>Not everyone is sold on the idea that the proposed benefit will be able to move a large number of Medicaid-covered infusion patients into the home.Take Option Care Health Chief Strategy Officer Richard Denness, for example.&ldquo;The proposed CMS rule is deeply flawed because it limits reimbursement for home infusion services to just the days when a nurse is present in the patient&rsquo;s home,&rdquo; Denness told HHCN. &ldquo;The proposed rule does not reflect the reality of how most patients receive home infusion therapy.&rdquo;Bannockburn, Illinois-based Option Care is one of the largest home infusion providers in the country, serving patients in all 50 states and delivering more than 2 million home infusion doses each month across all therapy areas.Denness says the proposed benefit misunderstands and devalues all the elements that go into home infusion, leaving the cost of the service still largely out of reach.&ldquo;For most patients, a nurse is only present once per week, and home infusion therapy is coordinated by specialty pharmacists who design the therapy in coordination with a patient&rsquo;s physician, assess the patient, monitor for adverse drug reactions, coordinate care with a care team and make modifications to the plan of care as necessary,&rdquo; he said.Without access to reimbursement for professional services, home infusion can be unaffordable for Medicare patients, Denness said.As such, Option Care continues to work with other members of the National Home Infusion Association (NHIA) to advocate for improved reimbursement from CMS.&ldquo;Any patient that is a candidate for home infusion should have that option, and we&rsquo;re working to help make that possible,&rdquo; Denness said.CMS is accepting comments on the proposed rule, which includes the permanent home infusion benefit, through September 9.

Starting in 2021, Medicare patients could have access to a new permanent home infusion benefit. The Center for Medicare & Medicaid Services (CMS) proposed the benefit in July as part of its proposed home health payment rule, with the goal being to move more care into the home.
While some view the proposed benefit as a win and an opportunity creator...

Proposed Home Infusion Benefit Exciting to Some, ‘Deeply Flawed' to Others

Invivyd, Inc announced the formation of the SPEAR (Spike Protein Elimination and Recovery) Study Group, a collaborative clinical and translational research initiative to evaluate monoclonal antibody therapies, including pemivibart (Pemgarda), for potential treatment of Long COVID and COVID-19 Post-Vaccination Syndrome (PVS). The initiative responds

Invivyd Forms SPEAR Study Group to Investigate Pemivibart for Long COVID and Post-Vaccination Syndrome

1. Among adult patients with migraine headaches, the use of a prescribed digital health app did not reduce the number of migraine days compared with a control app consisting of only migraine diary features.
Evidence Rating Level: 1 (Excellent)
Current management of migraines includes both pharmacological and nonpharmacological approaches, including

2 Minute Medicine Rewind July 7, 2025

Key Takeaways
Sunvozertinib is the first approved targeted oral treatment for NSCLC with EGFR exon20ins, filling a significant treatment gap.
The WU-KONG1 Part B study demonstrated sunvozertinib's efficacy, with a 54.3% overall response rate and a 90.8% disease control rate.
The FDA has granted accelerated approval to sunvozertinib (Zegfrovy; Dizal

Sunvozertinib Approved by FDA as Oral Treatment of NSCLC With EGFR Exon 20 Insertion Mutations

Key Takeaways
Nivolumab plus ipilimumab showed superior PFS and OS compared to durvalumab plus tremelimumab and atezolizumab plus bevacizumab in unresectable HCC.
The study used matching-adjusted indirect comparisons due to the lack of direct head-to-head trials among the regimens.
First-line nivolumab (Opdivo) plus ipilimumab (Yervoy) demonstrated

MAIC Analysis Suggests PFS, OS Advantage With Nivolumab/Ipilimumab Over Other First-Line IO Regimens in HCC

Neonatal PICC subspecialty in neonatal vascular access
Abstract:
This perspective review examines the evolving role of neonatal peripherally inserted central catheters (n-PICCs) as a distinct subspecialty within neonatal vascular access. n-PICCs are indispensable for delivering long-term intravenous therapies in critically ill neonates. The review

Neonatal PICC subspecialty in neonatal vascular access – Full Text

In advanced HER2-positive metastatic breast cancer, treatment options beyond the third line become less standardized and are often described as the “wild West” due to a lack of clear consensus. After exhausting first through third-line therapies—including combinations such as trastuzumab, pertuzumab, tucatinib, and T-DM1—clinicians often rely on a

Expert Insights: Later-Line Treatment Strategies for HER2+ Metastatic Breast Cancer

The current status and evolution of hemodialysis catheters
Abstract:
Chronic kidney disease (CKD) represents a growing global health burden, with an increasing number of CKD patients progressing to renal failure or end-stage renal disease (ESRD). Hemodialysis is widely regarded as the usual treatment modality for patients with ESRD. Currently, more

The current status and evolution of hemodialysis catheters – Full Text

A new analysis from the PREPARE (Pitavastatin to REduce Physical Function Impairment and FRailty in HIV) trial found that 52% of middle-aged adults with HIV experienced measurable declines in physical function over time. Published in the June 2025 issue of Open Forum Infectious Diseases, the study highlights the importance of identifying individual

PREPARE Trial: Over Half of Middle-Aged Adults With HIV Experience Physical Function Decline

The FDA has approved SIR-Spheres Y-90 resin microspheres as treatment for patients with hepatocellular carcinoma (HCC), according to a press release from Sirtex Medical.1
Results from the DOORwaY90 study (NCT04736121) led to the approval. The safety and efficacy of selective internal radiation therapy using the SIR-Spheres Y-90 resin microspheres w

FDA Approves SIR-Sphere Y-90 in HCC

1. In this prospective cohort study, body mass index-specific waist circumference (WC) thresholds were found to improve mortality risk stratification in a nationwide sample of women.
2. This effect was consistent even after removing potential confounders such as diet, physical activity, and sleep.
Evidence Rating Level: 2 (Good)
Study Rundown: Body

Body mass index-specific waist circumference thresholds may improve mortality risk stratification in women

Ivosidenib showed promising efficacy in IDH1-mutated cholangiocarcinoma, with a median PFS of 4.7 months and OS of 15.5 months in the ProvIDHe study.
The study enrolled 285 patients, focusing on safety and secondary outcomes like PFS, OS, and quality of life measures.
Ivosidenib (Tibsovo) displayed preliminary efficacy for the treatment of patients

Ivosidenib Has Preliminary Real-World Activity in IDH1-Mutated Cholangiocarcinoma

Adding oral vancomycin to a systemic antibiotic treatment of a non- Clostridioides difficile infection (CDI) to prevent CDI recurrence in at-risk patients was associated with a lower rate of recurrence than in those not receiving vancomycin in a placebo-controlled trial1, but the difference was not statistically significant and the rates were high

Effectiveness of Oral Vancomycin in Preventing C diff Remains Uncertain after Trial

Patient enrollment has been finalized for the single-arm phase 3 UTOPIA trial (NCT06331299) evaluating intravesical solution for UGN-103, a mitomycin-based formulation, in patients with recurrent low-grade intermediate risk non–muscle invasive bladder cancer (NMIBC), according to a press release from the developer, UroGen Pharma.1
The trial has enr

Patient Enrollment for Phase 3 UGN-103 Trial in LG-IM-NMIBC Complete

1. In this cross-sectional study, approved label populations were broader overall compared to trial populations for new drugs in the United States and Europe.
2. The category of patient fitness most often exhibited broader label populations than trial populations, followed by disease severity.
Evidence Rating Level: 3 (Average)
Study Rundown: The U

Approved label populations may be broader than trial populations for new drugs

Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.
These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology.
Here’s what you may have missed:

Five Under 5: Top Oncology Videos for the Week of 6/29

Nicholas James Hornstein, MD, PhD, discussed results from the phase 3 CHALLENGE trial (NCT00819208) that were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. According to Hornstein, this trial has garnered significant attention, particularly for its exploration of exercise as a therapeutic intervention in colorect

The CHALLENGE Trial Helps Redefine Adjuvant Therapy with Exercise in CRC

Key Takeaways
AS01-adjuvanted vaccines, Arexvy and Shingrix, are linked to a reduced dementia risk, increasing dementia-free time by up to 37%.
The study found no significant difference in dementia risk reduction between receiving one or both AS01 vaccines.
New study findings published by investigators in Nature found that 2 AS01-adjuvanted vaccine

Shingles and RSV Vaccines Show Promise Against Dementia

Contact

Advertise

Other industries

Empower vascular access teams with tools that streamline workflows, enhance teamwork, and improve outcomes.

Tools for Efficient Vascular Access | Salubrity Online

Gebauer’s Pain Ease® works in just 4-10 seconds!

Give patients the comfort they deserve

Ivenix Infusion System

You have several options—but you also have several reasons to choose one above the rest.
Learn more now.


Prescribing IVIg?

AVA Consensus Statement recommend adhesives like gum mastic to secure PIVC dressings and devices.